FluxMPS™ RPMI 1640 Medium, High Glucose & 25mM HEPES w/o Phenol Red: 1X Liquid

FluxMPS™ RPMI 1640 Medium, High Glucose & 25mM HEPES w/o Phenol Red: 1X Liquid

FluxMPS™ DCP?RPMIGH?R1X is a Microfluidics Suitable, quadruple-stage ultra-filtered (0.1 µm ×2 + 0.04 µm ×2) 1X liquid RPMI 1640 medium engineered for organ-on-a-chip (OoC) and microphysiological system (MPS) platforms. The quadruple-stage train reaches a 0.04 µm final cut-off — five times finer than the 0.22 µm membranes used for conventional sterile filtration.

• High-glucose (4500 mg/L) RPMI 1640 formulation buffered with both 25 mM HEPES and sodium bicarbonate (2000 mg/L), prepared without phenol red for low-background imaging
• Quadruple-stage filtration train (0.1 µm ×2 + 0.04 µm ×2) reaching a validated 0.04 µm final cut-off
• Endotoxin release specification < 0.05 EU/mL (LAL, USP <85>), controlled per manufacturing batch
• Manufactured under an ISO 13485:2016 quality management system with full lot traceability
• 40 verified components across inorganic salts, amino acids, vitamins and other constituents, each with CAS traceability
• Contains L-glutamine (300 mg/L) and sodium pyruvate (110 mg/L) as ready-to-use carbon/nitrogen supplements
• Custom pH, glucose, HEPES, salt and nutrient modifications available on request

Engineered where standard media fails

Conventional 0.22 µm–filtered media passes mycoplasma-sized particulates, subvisible aggregates, and manufacturing debris that can confound sensitive cell assays and foul microfluidic channels.

Quadruple-stage filtration system

Four serial filtration stages — two dedicated 0.1 µm prefilter + 0.04 µm final-filter pairs, run in series — reaching a validated 0.04 µm final pore size prior to aseptic fill.

1. 1

   0.1 µm Prefiltration I — Large Particulate Removal

   Removes large aggregates, cell debris and protein clumps; protects the first 0.04 µm final filter and extends its service life.

2. 2

   0.04 µm Final filtration I — Sub-Micron Polishing

   First 0.04 µm pass; retains particulates and aggregates in the mycoplasma size range (0.2–0.3 µm) that a standard 0.22 µm filter does not.

3. 3

   0.1 µm Prefiltration II — Redundant Protection

   A second, dedicated 0.1 µm prefilter protects the second 0.04 µm cartridge, giving the train full redundancy rather than a single pass.

4. 4

   0.04 µm Final filtration II — Polish

   Second 0.04 µm pass; final polishing filtration immediately prior to aseptic fill & finish.

OoC and MPS applications

FluxMPS™ DCP-RPMIGH-R1X delivers Microfluidics Suitable, ultra-filtered purity for organ-on-a-chip and microfluidic applications.

Automated Bioreactors & Robotics

An optional 0.01 µm (10 nm) MPS Grade ultra nano-filtered variant of this formulation is available on request for automated bioreactors and robotic perfusion systems.

• Total Particulate Exclusion: 0.01 µm filtration removes nanoparticulate aggregates that foul automated systems
• Valve & Sensor Protection: Reduces micro-fouling risk in automated perfusion and recirculation systems
• Extended Perfusion Stability: Consistent nutrient delivery over long-duration culture runs

Inquiry Required: Contact support@diagnocine.com to request the 0.01 µm MPS Grade variant.

Analytical release specifications

Every lot is released against the full specification matrix below. Certificate of Analysis available: support@diagnocine.com.

Full composition (mg/L)

RPMI 1640 Medium, High Glucose & 25mM HEPES w/o Phenol Red: 1X Liquid — 40 ingredients across four composition groups (Inorganic Salts, Amino Acids, Vitamins, Others), organized in three tabs below, verified per lot with CAS numbers for raw-material traceability.

ISO 13485 manufacturing & compliance

Every batch of FluxMPS™ DCP-RPMIGH-R1X is manufactured under a certified ISO 13485:2016 quality management system with full lot traceability and multi-parameter QC release testing.

How DCP-RPMIGH-R1X compares

FluxMPS™ DCP-RPMIGH-R1X compared against published supplier specifications for cell culture media.

Comparison figures from published supplier specifications, accessed 2026-09-02. Suppliers that publish no numeric endotoxin specification are shown as "Not specified".

Frequently asked questions

Common questions about FluxMPS™ DCP-RPMIGH-R1X and its use in OoC and MPS applications.

Supporting literature

Curated peer-reviewed references relevant to OoC and MPS applications and FluxMPS™ ultra-filtered cell culture media.

1. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nature Biotechnology. 2014;32(8):760–772.doi:10.1038/nbt.2989
2. Sackmann EK, Fulton AL, Beebe DJ. The present and future role of microfluidics in biomedical research. Nature. 2014;507(7491):181–189.doi:10.1038/nature13118
3. Huh D, et al. Reconstituting organ-level lung functions on a chip. Science. 2010;328(5986):1662–1668.doi:10.1126/science.1188302
4. Ingber DE. Is it time for Reviewer 3 to request human organ chip experiments instead of animal validation studies? Advanced Science. 2020;7(22):2002162.doi:10.1002/advs.202002162
5. Maoz BM, et al. A linked organ-on-chip model of the human neurovascular unit reveals the metabolic landscape of brain disease. Nature Biotechnology. 2018;36:865–874.doi:10.1038/nbt.4226
6. Bhise NS, et al. A liver-on-a-chip platform with bioprinted hepatic spheroids. Biofabrication. 2016;8(1):014101.doi:10.1088/1758-5090/8/1/014101
7. Luni C, Serena E, Elvassore N. Human-on-chip for therapy development and fundamental science. Current Opinion in Biotechnology. 2014;25:45–50.doi:10.1016/j.copbio.2013.08.015
8. Erickson KA, Bhansali S. Mycoplasma contamination in cell cultures: a survey of incidence and approaches to prevention. Journal of the Association for Laboratory Automation. 2012;17(5):346–354.doi:10.1177/2211068212456089
9. van Duinen V, et al. Microfluidic 3D cell culture: from tools to tissue models. Current Opinion in Biotechnology. 2015;35:118–126.doi:10.1016/j.copbio.2015.05.002
10. Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–314.doi:10.1126/science.123.3191.309